Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects With Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath

NCT02371369 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT02371369
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02371369 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects With Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath
Lead sponsor
Daiichi Sankyo
Phase
Phase 3
Overall status
Completed
Start date
May 11, 2015
Completion date
April 30, 2021
Enrollment
120 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

giant cell tumors of the tendon sheath, pigmented villonodular synovitis, tenosynovial giant cell tumor